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Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is 
a chronic multifaceted illness whose clinical hallmarks 
include perceived bladder pain and irritative voiding 
symptoms, in the absence of easily identifiable pathology. 
Similarly, vulvodynia is a broad term imparted to varied 
forms of persistent vulvar pain of unknown origin. Once 
thought to be rare clinical entities, recent epidemiology 
suggests that these conditions are not only rather common, 
but also frequently co-exist. Furthermore, IC/BPS and 
vulvodynia often share co-morbidities. The apparent close 
clinical association between these syndromes may relate 
to similar embryological origins and/or multiple forms of 
shared pathologies. This article will examine the similarities 
between these conditions and therapeutic implications.
Common embryological derivations
Urogenital tissues share common embryological origins, 
which may account for the frequent coexistence of IC/BPS 
and vulvodynia (Figure 1). McCormack first reported on 
36 patients with focal vulvitis (vulvodynia) of those, 11 also 
had comorbid IC/BPS (1). Fitzpatrick et al. then published 
case reports of three women with coexisting IC/BPS and 
vulvodynia and discussed the significance of a disorder 
of the urogenital sinus (UGS)-derived epithelium for 
both diagnosis and treatment (2). Similar embryological 
derivations between tissues may also account for common 
complaints of urethral pain (a region that bridges the 
bladder and genital tissue) in both patient groups.
Indeed, urogenital tissues are of endodermal origin 
and derived from the cloacal membrane, a structure that 
is formed at the third fetal week. By the seventh week, 
a urorectal septum divides the cloacal membrane, thus 
separating it into an anterior urogenital and a posterior 
anal membrane (3). The urogenital membrane perforates to 
create the primary UGS, a structure that communicates with 
the amniotic cavity. A definitive UGS is formed with further 
partitioning that includes caudal phallic and pelvic regions. 
These regions will ultimately develop into the vaginal 
introitus and the female urethra/lower portion of vagina, 
respectively. The uterus, cervix, and upper portion of the 
vagina are derived from the Müllerian ducts (mesodermal 
tissue) after the ducts fuse and canalize with the UGS. 
Other endodermal derivatives of clinical importance are the 
Skene’s and Bartholin’s glands. “Hart’s line” found on the 
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Pathology
Over the past two decades, much basic research has been 
invested to defining the cause of both pain syndromes. 
Although lines of investigation for these conditions differ in 
many aspects, there are some commonalities of pathology 
that have been identified.
Mast cell involvement
Typical ly,  mast  cel ls  are associated with al lergic 
disorders and acute inflammatory responses, secreting 
numerous proinflammatory mediators; contributing to 
a variety of chronic inflammatory conditions such as 
intestinal ulceration, rheumatoid arthritis and Crohn’s 
disease. Additionally, they are found in stress-induced 
neuroinflammatory diseases including multiple sclerosis, 
migraines, atopic dermatitis, chronic urticaria, irritable 
bowel syndrome and IC/BPS (5). Vasoactive, nociceptive 
and proinflammatory molecules released from activated 
mast cells produce neuronal sensitization and secretion of 
neurotransmitters that further stimulate mast cells. It is this 
cycle that may contribute to the chronic voiding and pain 
symptoms associated with IC/BPS (6).
Similarly, enhanced mast cell activity has been identified 
in vulvodynia patients where histamine release is thought to 
stimulate peripheral pain transmitting neurons (C and A-δ 
fibers) (7-9). Borenstein et al. compared vestibular tissue 
from women with severe vulvodynia (n=40) for mast cell 
count and degranulation and nerve cell total area compared 
to controls (n=7). They found a significant increase in the 
total mast cell count (P=0.006; P=0.15) and degranulated 
mast cells (P=0.0001) in the vulvodynia patients compared 
to controls. The total nerve fiber area was found to be 
10 times higher in the vulvodynia group (4,190 μm2) 
compared to the control group (425 μm2) (P=0.01) (10).
Neurogenic inflammation, neuropathic pain, central 
sensitization
The role of the peripheral and central nervous systems in 
the pathogenesis of IC/BPS and vulvodynia is complex and 
profoundly incomplete. Clinical observations suggest that 
both of these pain syndromes have subtypes where pain 
is derived from the “end organ” and/or those where pain 
is generated at higher levels within the nervous system. 
Traditionally, treatment for these patients has been targeted 
to peripheral pathology; however, these therapies may be 
Figure 2 Endodermal derivatives on physical examination of adult 
are highlighted in yellow. Ectodermal derivatives are highlighted 
in blue.
Figure 1 Endodermal derivation of the urogenital system 
highlighted in yellow. (A) The descent of the urogenital septum 
(or fold) at week 7. Note the intact cloacal membrane formed by 
the juxtaposition of ectodermal and endodermal elements; (B) 
breakdown of the cloacal membrane between weeks 8-9 and the 
final division between the rectum and urogenital system; (C) final 
differentiation of endodermal structures at 12 weeks.
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inner aspect of the labia minor marks the final boundary 
between endodermal (UGS) and ectodermal derivatives 
(Figure 2). The upper portion of the UGS develops into 
the urinary bladder. Past embryological dogma suggested 
that the trigone of the bladder was derived from mesoderm; 
however, more recent investigations suggest that the entire 
bladder is of endodermal origin (4).
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insufficient due to altered central nervous system (CNS) 
processing.
From a neuroanatomical perspective, the female urinary 
and reproductive systems are innervated by the same sacral 
nerve pathways (11). This nerve innervation is responsible 
for both the motor/efferent and sensory/afferent pathways 
of the somatic and visceral systems (12). Additionally, the 
dorsal root ganglion cells at the thoracolumbar and sacral 
levels play a role in the transmission of painful sensations 
from the pelvis to the brain (13).
Much of the pain experienced by IC/BPS and vulvodynia 
patients appears to be neuropathic. Neuropathic pain is a 
primary excitatory disorder of the nervous system occurring 
through a variety of mechanisms such as infection, trauma, 
or with no apparent etiology. In patients with neuropathic 
pain, the injured nerve fibers fire spontaneously or at 
a lower threshold, the latter phenomenon accounting 
for the local allodynia (painful response to non-noxious 
stimuli) identified in many patients with IC/BPS and 
vulvodynia. Neurogenic inflammatory events may be 
part of this process whereby primary afferent nociceptors 
(primarily C-fibers but to a lesser extent also A-δ fibers) 
are stimulated with the subsequent release of inflammation 
provoking neuropeptides [e.g., substance P, calcitonin gene-
related peptide (CGRP), neurokinin A and B] and lead to 
a state of neurologic “wind-up” (6,8,13,14). Downstream 
clinical events typically include local vasodilation, edema, 
hyperalgesia and allodynia; all notable characteristics in 
certain subgroups of IC/BPS and vulvodynia. Neurogenic 
inflammation plays a role in local pain and inflammation, 
but also at referred sites (6,13). This may explain why 
patients with IC/BPS may experience referred pain in the 
vulva and patients with vulvodynia may experience referred 
pain in the bladder and urethra.
Abnormal pain processing, suggesting CNS sensitization, 
has been identified in IC/BPS and vulvodynia patients. 
Ness et al. demonstrated generalized lower thermal pain 
tolerances in IC/BPS patients than healthy controls (15). 
Previous studies in vulvodynia showed lower peripheral 
pain thresholds in both painful and non-painful areas when 
compared to healthy controls. (16-18).
Central processing abnormalities in vulvodynia were 
further investigated by functional MRI (fMRI). This revealed 
that when women afflicted with vulvodynia described 
pressure as painful, they had significantly higher activation 
levels in the insular and frontal cortical regions than did 
the healthy control group (19). Hampson et al. recently 
compared local (vulvar) and remote (thumb) pressure-
evoked pain processing via fMRI scans between women 
with vulvodynia (n=24), age-matched healthy controls 
(n=13), and positive controls with fibromyalgia (n=24) 
(for thumb pressure). Vulvodynia and fibromyalgia patients 
displayed similar insular brain activations that were greater 
than the healthy control patients in response to thumb 
pressure (P<0.005). Also, compared to the healthy controls, 
the vulvodynia group displayed greater levels of activation 
within the insula, dorsal mid cingulate, posterior cingulate 
and thalamus during thumb pressure (P<0.005) (20). 
Grey matter densities in areas that modulate pain and 
stress (e.g., parahippocampal gyrus, hippocampus and basal 
ganglia) were significantly higher in women with vulvodynia 
vs. controls (21).
Recent fMRI studies in IC/BPS demonstrated alterations 
in resting state oscillations and enhanced connectivity in 
sensory and motor networks in IC/BPS patients compared 
to controls. Increased connectivity was greatest in patients 
reporting pain during bladder filling (22). White matter 
abnormalities, many of which correlated to pelvic pain severity 
and urinary symptoms, were detected in female IC/BPS 
patients using diffusion tensor imaging or fractional 
anisotropy (23).
Hormonal influences
Endocrine dysregulation has been postulated to account 
for the development and/or maintenance of IC/BPS 
and vulvodynia. Symptom flares in these patients may in 
fact be modulated by the estrogen surge before menses 
that induces the release of histamine from mast cells 
resulting in increased amounts of substance P (24,25). 
A neuromodulatory role of estrogen on pain transmission 
at various sites has been documented (26). Gonadal 
hormones are also theorized to influence the CNS activity 
of neuromodulators involved in nociceptive processing (27). 
Clinically, this may impact patients with both IC/BPS 
and vulvodynia. A recent prospective study investigated 
the effect of local (topical) estrogen on urinary and sexual 
symptoms in premenopausal women with IC/BPS (28). 
A total of 34 women with IC/BPS were treated with topical 
estriol 3 times per week for 12 weeks. A total of 94.1% (32/34 
of the women) were diagnosed with concomitant vulvodynia. 
Results indicate a significant improvement of both urinary 
symptoms and sexual function (P<0.001, for both). 
Investigators theorize that women with these conditions 
are vulnerable to changes in sex steroid milieu thereby 
predisposing urogenital tissues to abnormal responses (28).
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Many IC/BPS patients report symptom exacerbation, or 
flares, perimenstually or around ovulation. Powell-Boone et al. 
conducted a small study on IC/BPS patients and healthy 
controls that showed a correlation between pain and urinary 
frequency scores and the phases of the menstrual cycle (29).
Several studies have shown a link between combined 
hormonal oral contraception and vulvodynia (30-32); 
however, other studies failed to demonstrate this correlation 
(33,34). Further investigations are warranted to determine 
the association between endogenous and exogenous gonadal 
hormones and the development and/or exacerbation of 
IC/BPS and vulvodynia.
Epidemiology
Epidemiology with regard to IC/BPS and vulvodynia has 
been primarily hampered by the varied definitions for these 
syndromes. Nevertheless, most investigations indicate 
that these conditions not only have a high prevalence and 
have common co-morbidities; but that they are frequently 
identified in the same patient.
Among women age 18 and over in the US, recent data 
suggest between 3.3 and 7.9 million women have symptoms 
of IC/BPS (35). The prevalence of vulvodynia has been 
estimated to range between 4-16%, effecting more than 
2.4 million women in the US (36-38). The association between 
IC/BPS and vulvodynia is often reported, with 25% of women 
with IC/BPS also reporting to have vulvodynia (28,37,39,40). 
Gordon et al. conducted an Internet-based survey of 
428 women with self-reported vulvar pain and found that 
11% had an IC/BPS diagnosis (41). Nguyen et al. conducted a 
survey of 1,457 women with diagnosed vulvodynia [generalized 
(involves entire vulva) n=467, localized (involves a specific 
portion or component of the vulva) n=639, or both n=351] and 
the presence of co-morbid pain conditions. They found that 
18.8% of the generalized group, 14.7% of the localized group, 
and 27.9% of the group with both types of vulvodynia also 
reported co-morbid IC/BPS (P<0.001) (42).
Patients often have overlapping symptoms making 
diagnosis of one or both conditions all the more difficult. 
Frequency of both conditions is often underestimated due 
to the fact that many in the medical community believe 
these conditions to be psychological in origin or because 
women reluctant to discuss their symptoms (43).
Comorbid conditions
IC/BPS and vulvodynia are frequently associated with 
other pain syndromes. Interestingly, recent non-population 
based studies suggest that irritable bowel syndrome 
and fibromyalgia are the two most prevalent comorbid 
conditions associated with both conditions. (42,44). Other 
co-morbid conditions commonly seen in both IC/BPS and 
vulvodynia are temporal mandibular joint and muscle disease 
(TMD) and chronic fatigue syndrome (CFS). As previously 
mentioned, IC/BPS and vulvodynia are frequently 
seen as co-morbid to each other. Both Nickel et al. 
and Nguyen et al. indicate that the prevalence of multiple 
comorbidities increases with symptom severity (42,44).
Hypertonic pelvic floor dysfunction (HTPFD) is 
commonly seen in both conditions. Many patients with 
IC/BPS and vulvodynia present with muscle tenderness, 
myofascial pain, spasticity, voiding dysfunction and 
dyspareunia which are also manifestations of HTPFD. 
Approximately 50-87% of patients with IC/BPS are 
diagnosed with HTPFD (45). Yong et al. recently reported 
the prevalence of PFD (defined as pelvic floor muscle 
tenderness) in 189 women with chronic pelvic pain 
compared to 32 healthy controls. A total of 40% of the 
women with chronic pelvic pain (75/189) had concomitant 
PFD vs. 13% of controls (4/32) (46). While it is unclear 
if HTFPD results from chronic pain of IC/BPS and 
vulvodynia or if it is a precipitating factor, HTPFD can 
exacerbate symptoms and can itself worsen in response to 
IC/BPS or vulvodynia flares.
Quality of life (QOL)
Chronic urogenital pain syndromes may have a profound 
effect upon QOL resulting in feelings of hopelessness 
and helplessness,  depression as well as negatively 
impacting personal relationships. A case-controlled 
survey demonstrated a correlation between stress, anxiety, 
depression and catastrophizing to IC/BPS symptoms and 
a decreased QOL (44). Similar reports demonstrate when 
compared to controls, women with vulvar pain reported 
significantly worse mental health-related QOL, lower levels 
of happiness in couple relationships, higher trait anxiety, 
increased somatization and catastrophizing related to 
dyspareunia (47-49).
Behavioral interventions emphasizing a self-management 
approach, such as cognitive behavioral therapy (CBT), are 
effective treatment option for both conditions. Numerous 
studies have shown that CBT increases perceived control 
in patients with chronic pain by reducing pain, helplessness 
and psychological distress (50-54). CBT has been shown 
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to reduce catastrophizing, decrease pain and improve 
sexual functioning in women with vulvodynia and has been 
recommended for patients with IC/BPS (55-57).
Sexual function
Sexual dysfunction strongly impacts the QOL in patients 
with IC/BPS and vulvodynia. It has been postulated that 
pain mediates sexual dysfunction and its associated effects 
on QOL. A higher prevalence of moderate to severe 
sexual dysfunction has been identified in IC/BPS patients 
compared to controls (58,59).
Bogart et al. conducted a telephone survey of women with 
IC/BPS (n=1,469) to determine the prevalence of sexual 
dysfunction compared to the general population. A total of 
88% of the women with a sexual partner reported having 
sexual dysfunction vs. 43% in the general population (57). 
Gardella et al. evaluated women diagnosed with IC/BPS 
(n=47) and a control group (n=47) for the characteristics of 
vulvodynia. The prevalence of vulvodynia was 85.1% in the 
IC/BPS group compared to 6.4% in controls (P<0.0001). 
Dyspareunia was described as “unbearable” in 31.9% of the 
IC/BPS group compared to 4.3% of controls (P=0.0001) (39).
Limiting or avoidance of sexual activity due to associated 
pain is common in patients with IC/BPS and vulvodynia. 
What used to be arousing and satisfying for the couple 
may now be a source of pain. Communication, self-care, 
changes in sexual scripts and discussion of non-penetrative 
alternatives are all important aspects of managing 
sexual function with chronic pelvic pain syndromes. 
A multidisciplinary approach with urology, physical therapy 
and sex therapy is fundamental to targeting the multiple 
facets of chronic urogenital pain and altered sexual function.
Clinical implications
Similarities in treatment options
IC/BPS and vulvodynia are complex pain syndromes 
accompanied by multiple pain generators, i.e., HTPFD, 
where symptom improvement (or lack thereof) rests upon 
a gauntlet of trial and error therapies. Unfortunately, there 
is a paucity of literature detailing studies for the treatment 
of IC/BPS and vulvodynia. Most clinical trials thus far 
have been limited to small label open or rare placebo-
controlled studies, usually too small to yield useful data (43). 
Nonetheless, some useful information has been garnered 
from these investigations; and when combined with 
expert opinion, some interesting similarities between the 
treatments of IC/BPS and vulvodynia can be identified. 
These similarities may have potential impact upon 
streamlining patient care, particularly for those patients 
who suffer from both ailments. Furthermore, similarities 
with respect to treatment response may have some bearing 
on the underlying pathophysiologies of these conditions.
Behavioral modification
First-line treatment for both IC/BPS and vulvodynia 
employs behavioral modification and self-care measures. 
Patient empowerment from the initial visit is imperative. 
This can be accomplished by giving them information 
pertaining to online resources (e.g., medically accurate 
websites, advocacy groups), support groups, books, etc.
Stress reduction and relaxation techniques are strongly 
recommended. Data suggest that women with urogenital 
pain syndromes have higher levels of stress than healthy 
controls (60-63). Rothrock et al. conducted a prospective 
comparison of 45 IC/BPS patients to 31 age-matched 
controls in order to determine how stress levels in daily life 
impacts their symptoms. Participants with IC/BPS were 
asked to track their daily urinary frequency, urgency, bladder 
pain, and stress for 1 month. Results showed that increased 
levels of stress were related to greater pain and urgency 
in the IC/BPS group, but not in the control group (63). 
Clinical observations suggest that stress exacerbates 
symptoms and that symptoms tend to worsen stress. 
As such, multimodal treatments are suggested for both 
conditions to break frequently identified vicious cycles of 
pain.
Physical therapy
Physical therapy, once rarely used for the treatment of 
IC/BPS and vulvodynia, has become a mainstay in the 
treatment algorithm. Pelvic floor physical therapy is now 
more widely available and effective in the treatment of 
both pain syndromes. As previously mentioned, patients 
with both IC/BPS and vulvodynia often exhibit pain, taut 
bands and/or trigger points in the muscles of the pelvic 
floor. Often, patients are found to have involvement of the 
external muscles of the pelvis, low back, abdomen and lower 
extremities. Physical therapists with a specialized expertise 
in chronic urogenital pain employ treatment techniques 
including internal and external myofascial release and soft 
tissue mobilization in addition to stabilization, stretching 
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exercises and biofeedback. It is important to note that there 
is no evidence physical therapy strengthening exercises 
(Kegel’s) improve symptoms. It has been noted that this 
type of pelvic floor therapy may in fact worsen pelvic pain 
conditions (64).
Hartmann et al. performed a retrospective review on 
women with vulvodynia who were treated with physical 
therapy (n=24). They reported that 71% showed greater 
than 50% improvement in symptom reduction (65). 
Upon interviewing 35 women after completion of a 
multimodal physical therapy program, Bergeron et al., 
found that 71% reported complete, great or moderate 
improvement (66). A small, prospective study of 13 women 
with vulvodynia completed eight sessions of pelvic floor 
physical therapy. They demonstrated that physical therapy 
led to normalization of pelvic floor muscle tone, significant 
reduction in pain during vaginal palpation, and decreased 
pain during gynecological exams and sexual intercourse (67).
A large randomized controlled trial (RCT) compared 
myofascial physical therapy to global therapeutic massage 
in IC/BPS patients (n=81). Participants were randomized 
to either group for ten 60-minute sessions over 12 weeks. A 
total of 59% of the physical therapy group reported moderate 
or marked improvement, compared to 26% in the massage 
group on the global response assessment (P=0.0012) (68).
Oral therapies
Many oral therapies prescribed can be used interchangeably 
for the treatment of both IC/BPS and vulvodynia.
Tricyclic antidepressants (TCA) are commonly used 
in the treatment of many chronic pain conditions with a 
neuropathic component. The most common TCAs used in 
the treatment of IC/BPS and vulvodynia are amitriptyline 
or nortriptyline and are thought to work by: (I) central 
and peripheral anticholinergic actions at certain receptor 
sites; (II) block reuptake of serotonin and norepinephrine; 
(III) block H1-histaminergic receptors thereby inhibiting 
mast cell release; (IV) have a sedative effect related to 
their antihistaminic properties; (V) desensitizes alpha 
two receptors on central noradrenergic neurons; and (VI) 
stimulate beta-adrenergic receptors in the bladder (69,70).
Munday et al. reported a 47% complete response to 
amitriptyline for the treatment of vulvodynia (n=33), 
however, the investigators were also employing behavioral 
modification and psychological support (71). Reed et al. 
evaluated 162 women prescribed a TCA (amitriptyline, 
desiprimine or another tricyclic antidepressant) for vulvodynia. 
Data show at the first follow-up visit at approximately 
3 months, 49 of the 83 women taking the TCAs improved by 
50%, compared to 30 of the 79 not taking TCAs (improvement 
rate =38%, P=0.007). They demonstrated that women taking 
TCAs for vulvodynia have greater pain improvement than 
women not taking these medications (72).
Hanno and Wein were the first to report a therapeutic 
response in an IC/BPS patient being concurrently treated 
for depression with amitriptyline (73). Results of a placebo-
controlled, double-blind trial of 48 patients with IC/BPS 
showed that after 4 months on amitriptyline (25-75 mg, 
self-titrating dose), 42% of patients (n=10) on the medication 
had a greater than 30% decrease in overall symptom score 
compared to 12.5% of those on placebo (n=3) (P<0.001). Pain 
and urgency improved in the amitriptyline group compared 
to placebo (P<0.001) and 63% (n=15) of the amitriptyline 
group reported good or excellent satisfaction with treatment 
outcome vs. 4% (n=1) of the placebo group (P<0.001) (74). 
Additional investigations have shown similar efficacy of 
TCAs for IC/BPS (75-79).
The biggest problem with the use of TCAs in treating 
both conditions is the potential adverse effects that 
can develop. Some adverse effects that may preclude 
continuation with the medication include anticholinergic 
effects (constipation, dry mouth, urinary retention), fatigue, 
weight gain, sexual dysfunction and cardiac arrhythmias (70).
Anticonvulsants are often employed for the treatment 
of IC/BPS and vulvodynia. Anticonvulsants such as 
gabapentin, and pregabalin, have been effective in treating 
diabetic neuropathy, post herpetic neuralgia and other 
diverse pain syndromes of neuropathic origin. The 
mechanism of action by which they are thought to improve 
pain is through binding to the alpha 2-delta subunit of 
voltage-gated of calcium channels thereby decreasing the 
release of glutamate, norepinephrine and substance P (80). 
Pregabalin has also exhibited anxiolytic effects in RCTs of 
generalized anxiety disorder, which may prove beneficial for 
patients with chronic urogenital pain conditions (81,82).
Ben-David and Friedman first published efficacy with 
using gabapentin for treating women with vulvodynia 
(n=17). A total of 82% (n=14) had partial or complete 
symptom relief with gabapentin therapy by 2 to 4 weeks of 
treatment. Follow-up extended between 26 and 32 weeks 
without any reported cases of late failure of therapy (83). 
A retrospective chart review of 152 women with vulvodynia 
treated with gabapentin by Harris and colleagues showed 
98 (64%) had resolution of at least 80% of their symptoms, 
and 49 (32%) did not have adequate response. They also 
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found that patients with a longer period of untreated illness 
seemed to have a less favorable response to therapy (P value 
not less than 0.05) (84). Further reports show that gabapentin 
improves vulvodynia symptoms either as monotherapy or 
as adjuvant therapy (85,86). Currently underway is the first 
double-blind, placebo-controlled, crossover study to evaluate 
the efficacy of extended release gabapentin, up to 300 mg/day 
in the treatment of vulvodynia (87).
The use of gabapentin in the treatment of IC/BPS 
is mainly from anecdotal reports. Sasaki et al. evaluated 
21 patients with refractory of genitourinary pain, including 
eight with interstitial cystitis and two with vulvar pain. 
Ten of the 21 patients treated with gabapentin reported 
subjective improvement in their symptoms; five of the eight 
patients with IC/BPS reported improvement (88).
Antihistamines have been used in the treatment of 
IC/BPS for decades. The most common medication used 
is hydroxyzine, which can block neuronal activation of 
mast cells (89). Sedation is a common side effect with 
this medication, so some clinicians have begun to use 
montelukast, a leukotriene receptor antagonist. Montelukast 
at 10 mg/day has been used in the treatment of both 
IC/BPS and vulvodynia with promising results (90,91). 
Authors proposed that leukotriene receptor antagonist has 
antihistamine action and may modulate the exaggerated 
proinflammatory activity.
Conclusions
Many similarities exist between IC/BPS and vulvodynia 
including clinical presentation, co-morbid conditions, and 
similar responses to medical interventions. Closer examination 
reveals commonalities in embryologic origins. Recognition of 
possible neuropathic involvement and central sensitization in 
conjunction with fMRI changes has far-reaching implications 
for improving treatment options. Further research is needed 
to determine whether these conditions are manifestations of a 
more global chronic urogenital pain syndrome.
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